{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:41:20Z","timestamp":1788050480083,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the efficacy and safety of interferon (IFN) alpha-2b eye drops in preventing pterygium recurrence after the bare sclera technique.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Sixty eyes in 53 patients who underwent treatment for primary pterygium (the length of corneal invasion ranged from 2 to 4 mm) were enrolled in this prospective study. All patients were divided in chronological sequence into 2 groups. The control group included the first 30 eyes, whereas the treatment group included the next 30 eyes. After treatment with the bare sclera technique, levofloxacin and 0.1% fluorometholone eye drops were used 4 times a day for 3 months after surgical excision in both groups. In addition, IFN alpha-2b eye drops were applied in the treatment group 4 times a day for 3 months. Throughout an 18-month follow-up period, all patients in both groups were examined 1 day, 10 days, 1 month, 3 months, 6 months, 12 months, and 18 months after surgery. The main outcome measures were pterygium recurrence, conjunctival redness and thickness, and neovascularization and complications (ie, delayed conjunctival healing, persistent corneal epithelial defection, conjunctival granuloma, and scleral melting and necrosis).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The recurrence rates in the control group and the treatment group at the end of the sixth month were 29.2% and 3.7%, respectively, and the rates were significantly different between the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.019). Up to 12 months after surgeries, the recurrence rate was 33.3% in the control group and 7.4% in the treatment group, and the difference between the 2 groups was statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.048). The rates at the end of 18 months were the same. During the follow-up period, no complications were observed except for 1 conjunctival granuloma (in the treatment group) and 2 corneal epithelial defects (one in the control group and the other in the treatment group).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Administration of IFN alpha-2b eye drops after the bare sclera technique appear safe and effective in reducing the recurrence of pterygium.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000001995","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T05:46:53Z","timestamp":1562824013000},"page":"1239-1244","source":"Crossref","is-referenced-by-count":16,"title":["Interferon Alpha-2b Eye Drops Prevent Recurrence of Pterygium After the Bare Sclera Technique: A Single-Center, Sequential, and Controlled Study"],"prefix":"10.1097","volume":"38","author":[{"given":"Mingyang","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10792-016-0358-5","article-title":"Developments and current approaches in the treatment of pterygium","volume":"37","author":"Hacioglu","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OPTH.S55259","article-title":"An update on the surgical management of pterygium and the role of loteprednol etabonate ointment","volume":"8","author":"Sheppard","year":"2014","journal-title":"Clin Ophthalmol."},{"key":"R3-20230912","first-page":"522","article-title":"Clinical analysis of risk factors contributing to recurrence of pterygium after excision and graft surgery","volume":"8","author":"Hovanesian","year":"2015","journal-title":"Int J Ophthalmol."},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ophtha.2012.08.010","article-title":"Prevalence, treatment, and outcomes of coexistent ocular surface squamous neoplasia and pterygium","volume":"120","author":"Kim","year":"2013","journal-title":"Ophthalmology"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00003226-200103000-00010","article-title":"Detection of herpes simplex virus and human papilloma virus in ophthalmic pterygium","volume":"20","author":"Detorakis","year":"2001","journal-title":"Cornea"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/eye.2011.312","article-title":"Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia","volume":"26","author":"Di Girolamo","year":"2012","journal-title":"Eye (Lond)"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/eye.2012.194","article-title":"Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium","volume":"26","author":"Ling","year":"2012","journal-title":"Eye"},{"key":"R8-20230912","first-page":"166","article-title":"Lymphatic microvessel density as a predictive marker for the recurrence time of pterygium: a three-year follow-up study","volume":"19","author":"Lin","year":"2013","journal-title":"Mol Vis."},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.sjopt.2010.10.013","article-title":"The recurrence of pterygium after different modalities of surgical treatment","volume":"25","author":"Salman","year":"2011","journal-title":"Saudi J Ophthalmol."},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1542-0124(12)70103-9","article-title":"The pathogenesis of pterygium: current concepts and their therapeutic implications","volume":"6","author":"Chui","year":"2008","journal-title":"Ocul Surf."},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001622-200311000-00005","article-title":"Interferons: mechanisms of action and clinical applications","volume":"15","author":"Parmar","year":"2003","journal-title":"Curr Opin Oncol."},{"key":"R12-20230912","first-page":"2489","article-title":"Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res."},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","article-title":"Retrospective comparative study of topical interferon alpha 2b versus mitomycin C for primary ocular surface squamous neoplasia","volume":"36","author":"Kusumesh","year":"2017","journal-title":"Cornea"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"bcr2016218344","DOI":"10.1136\/bcr-2016-218344","article-title":"Ocular surface squamous neoplasia treated with topical interferon alpha 2b","volume":"2017","author":"Pujari","year":"2017","journal-title":"BMJ Case Rep."},{"key":"R15-20230912","first-page":"1","article-title":"Long-term efficacy and safety of interferon alpha-2a in the treatment of Chinese patients with Behcet's uveitis not responding to conventional therapy","author":"Yang","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/ICO.0000000000001200","article-title":"Comparative evaluation of tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal keratoconjunctivitis: a randomized, double-masked study","volume":"36","author":"Zanjani","year":"2017","journal-title":"Cornea"},{"key":"R17-20230912","first-page":"138","article-title":"Treatment of encapsulated blebs with slit-lamp needling and subconjunctival interferon injection","volume":"26","author":"Mao","year":"2011","journal-title":"Eye Sci."},{"key":"R18-20230912","first-page":"197","article-title":"Clinical study on interferon treatment of early scarring in filtering bleb","volume":"26","author":"Wang","year":"2011","journal-title":"Eye Sci."},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/2008-322X.183917","article-title":"Correlations between histopathologic changes and clinical features in pterygia","volume":"11","author":"Safi","year":"2016","journal-title":"J Ophthalmic Vis Res."},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2415-12-38","article-title":"Preoperative factors influencing success in pterygium surgery","volume":"12","author":"Torres-Gimeno","year":"2012","journal-title":"BMC Ophthalmol."},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcrs.2017.03.002","article-title":"Surgical techniques and adjuvants for the management of primary and recurrent pterygia","volume":"43","author":"Hovanesian","year":"2017","journal-title":"J Cataract Refract Surg."},{"key":"R22-20230912","first-page":"1849","article-title":"The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium","volume":"6","author":"Kareem","year":"2012","journal-title":"Clin Ophthalmol."},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/eye.2016.29","article-title":"Five-fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium","volume":"30","author":"Bekibele","year":"2016","journal-title":"Eye (Lond)"},{"key":"R24-20230912","first-page":"1067","article-title":"Bare sclera resection followed by mitomycin C and\/or autograft limbus conjunctiva in the surgery for pterygium: a meta-analysis","volume":"8","author":"Olaniyan","year":"2015","journal-title":"Int J Ophthalmol."},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0161-6420(03)00091-5","article-title":"Subconjunctival mitomycin C as adjunctive therapy before pterygium excision","volume":"110","author":"Donnenfeld","year":"2003","journal-title":"Ophthalmology"},{"key":"R26-20230912","first-page":"465","article-title":"Mitomycin C in pterygium treatment","volume":"9","author":"Martins","year":"2016","journal-title":"Int J Ophthalmol."},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ophtha.2012.06.066","article-title":"Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology","volume":"120","author":"Kaufman","year":"2013","journal-title":"Ophthalmology"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/ICO.0000000000000384","article-title":"Mitomycin C-associated scleral stromalysis after pterygium surgery","volume":"34","author":"Lindquist","year":"2015","journal-title":"Cornea"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/ICO.0b013e3182772d4e","article-title":"Topical application of bevacizumab as an adjunct to recurrent pterygium surgery","volume":"32","author":"Ozgurhan","year":"2013","journal-title":"Cornea"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","article-title":"Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium","volume":"28","author":"Wu","year":"2009","journal-title":"Cornea"},{"key":"R31-20230912","first-page":"22","article-title":"Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial","volume":"9","author":"Shin","year":"2014","journal-title":"J Ophthalmic Vis Res."},{"key":"R32-20230912","first-page":"512","article-title":"Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?","volume":"7","author":"Karalezli","year":"2014","journal-title":"Int J Ophthalmol."},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3341\/kjo.2015.29.6.375","article-title":"A comparative study of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery","volume":"29","author":"Hwang","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/ICO.0000000000000037","article-title":"Bevacizumab in the treatment of pterygium: a meta-analysis","volume":"33","author":"Hu","year":"2014","journal-title":"Cornea"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0008-4182(05)80031-6","article-title":"Treatment of early pterygium recurrence with topical administration of interferon alpha-2b","volume":"40","author":"Esquenazi","year":"2005","journal-title":"Can J Ophthalmol."},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1167\/iovs.05-1130","article-title":"UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling","volume":"47","author":"Di Girolamo","year":"2006","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ceo.12268","article-title":"Interferon-alpha and interferon-gamma modulate Fas-mediated apoptosis in mitomycin-C-resistant human Tenon's fibroblasts","volume":"42","author":"Wang","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"R38-20230912","first-page":"35","article-title":"Molecular genetic alterations and viral presence in ophthalmic pterygium","volume":"6","author":"Detorakis","year":"2000","journal-title":"Int J Mol Med."}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000001995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:33:29Z","timestamp":1694547209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000001995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000001995","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,3]]}}}